Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28157993 | 0.88 | TSHR (0.47) | TSHRTRPA1ALDH1A1 | |
| SCHEMBL1301172 | 0.88 | TSHR (0.47) | TSHRTRPA1ALDH1A1 | |
| SCHEMBL2402735 | 0.87 | TRPA1 (0.38) | TSHRTRPA1 | |
| SCHEMBL5907099 | 0.82 | TSHR (0.50) | TSHRTRPA1ALDH1A1 | |
| SCHEMBL812293 | 0.80 | TSHR (0.40) | TSHRTRPA1 | |
| SCHEMBL12042669 | 0.79 | TSHR (0.44) | TSHRTRPA1ALDH1A1MAPK1ANPEP | |
| SCHEMBL7325421 | 0.79 | TSHR (0.44) | TSHRTRPA1ALDH1A1MAPK1ANPEP | |
| SCHEMBL12042668 | 0.79 | TSHR (0.44) | TSHRTRPA1ALDH1A1MAPK1ANPEP | |
| SCHEMBL12042667 | 0.79 | TSHR (0.44) | TSHRTRPA1ALDH1A1MAPK1ANPEP | |
| SCHEMBL108666 | 0.79 | TSHR (0.44) | TSHRTRPA1ALDH1A1MAPK1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | claimed |
| EP-2373678-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2011-10-12 | — | — | EP | claimed |
| US-20110237520-A1 | Anticancer Compounds | PHARMA MAR, SA (ES) | 2011-09-29 | — | — | US | claimed |
| WO-2010070078-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-06-24 | — | — | WO | claimed |
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | disclosed |
| US-20110237520-A1 | Anticancer Compounds | PHARMA MAR, SA (ES) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237520-A1 | Anticancer Compounds | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNE1 | TSHR 2831/4885TRPA1 3860/4885ALDH1A1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.